Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,309 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Janku F, et al. Among authors: kim kb. Oncotarget. 2015 May 20;6(14):12809-21. doi: 10.18632/oncotarget.3373. Oncotarget. 2015. PMID: 25980577 Free PMC article.
Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.
Janku F, Angenendt P, Tsimberidou AM, Fu S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ, Piha-Paul SA, Zinner RG, Bedikian AY, Overman MJ, Kee BK, Kim KB, Kopetz ES, Luthra R, Diehl F, Meric-Bernstam F, Kurzrock R. Janku F, et al. Among authors: kim kb. Oncotarget. 2015 Sep 15;6(27):24581. doi: 10.18632/oncotarget.5663. Oncotarget. 2015. PMID: 26405159 Free PMC article.
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, DeMarini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA. Falchook GS, et al. Among authors: kim kb. Lancet Oncol. 2012 Aug;13(8):782-9. doi: 10.1016/S1470-2045(12)70269-3. Epub 2012 Jul 16. Lancet Oncol. 2012. PMID: 22805292 Free PMC article. Clinical Trial.
BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
Kim J, Lazar AJ, Davies MA, Homsi J, Papadopoulos NE, Hwu WJ, Bedikian AY, Woodman SE, Patel SP, Hwu P, Kim KB. Kim J, et al. Among authors: kim kb. J Cutan Pathol. 2012 Sep;39(9):821-5. doi: 10.1111/j.1600-0560.2012.01950.x. Epub 2012 Jul 19. J Cutan Pathol. 2012. PMID: 22809251 Free PMC article. Clinical Trial.
Dabrafenib for treatment of BRAF-mutant melanoma.
Kainthla R, Kim KB, Falchook GS. Kainthla R, et al. Among authors: kim kb. Pharmgenomics Pers Med. 2013 Dec 31;7:21-9. doi: 10.2147/PGPM.S37220. eCollection 2014. Pharmgenomics Pers Med. 2013. PMID: 24516336 Free PMC article. Review.
Dabrafenib.
Kainthla R, Kim KB, Falchook GS. Kainthla R, et al. Among authors: kim kb. Recent Results Cancer Res. 2014;201:227-40. doi: 10.1007/978-3-642-54490-3_14. Recent Results Cancer Res. 2014. PMID: 24756796 Review.
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Hong DS, et al. Among authors: kim kb. Clin Cancer Res. 2015 Nov 1;21(21):4801-10. doi: 10.1158/1078-0432.CCR-14-3063. Epub 2015 Jul 13. Clin Cancer Res. 2015. PMID: 26169970 Free PMC article. Clinical Trial.
1,309 results